Health Catalyst’s (HCAT) “Buy” Rating Reiterated at SVB Leerink

Health Catalyst (NASDAQ:HCAT)‘s stock had its “buy” rating reaffirmed by equities researchers at SVB Leerink in a report issued on Sunday, AnalystRatings.com reports.

Several other research analysts have also issued reports on the company. Piper Sandler boosted their target price on Health Catalyst from $57.00 to $66.00 and gave the company an “overweight” rating in a research report on Friday, August 6th. Zacks Investment Research upgraded Health Catalyst from a “sell” rating to a “hold” rating in a research report on Tuesday, September 21st. Citigroup boosted their target price on Health Catalyst from $62.00 to $68.00 and gave the company a “buy” rating in a research report on Monday, August 9th. Raymond James boosted their target price on Health Catalyst from $66.00 to $70.00 and gave the company a “strong-buy” rating in a research report on Tuesday, August 10th. Finally, Canaccord Genuity boosted their target price on Health Catalyst from $60.00 to $64.00 and gave the company a “buy” rating in a research report on Friday, August 6th. One investment analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $60.00.

HCAT opened at $53.70 on Friday. The firm has a market cap of $2.50 billion, a P/E ratio of -17.10 and a beta of 0.63. Health Catalyst has a 12 month low of $31.65 and a 12 month high of $59.50. The stock has a 50-day moving average of $54.41 and a 200 day moving average of $53.26.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings results on Thursday, August 5th. The company reported ($0.40) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.42) by $0.02. The company had revenue of $59.63 million during the quarter, compared to analyst estimates of $56.68 million. Health Catalyst had a negative return on equity of 24.68% and a negative net margin of 62.31%. Analysts predict that Health Catalyst will post -1.83 earnings per share for the current year.

In related news, CAO Jason Alger sold 652 shares of the business’s stock in a transaction that occurred on Friday, September 3rd. The shares were sold at an average price of $54.23, for a total value of $35,357.96. Following the completion of the transaction, the chief accounting officer now owns 15,312 shares of the company’s stock, valued at $830,369.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Paul Horstmeier sold 10,750 shares of the business’s stock in a transaction that occurred on Tuesday, July 6th. The stock was sold at an average price of $57.01, for a total transaction of $612,857.50. Following the completion of the transaction, the chief operating officer now directly owns 123,879 shares of the company’s stock, valued at approximately $7,062,341.79. The disclosure for this sale can be found here. Insiders sold 149,451 shares of company stock valued at $8,202,064 in the last three months. 2.00% of the stock is currently owned by insiders.

Several hedge funds have recently modified their holdings of HCAT. BlackRock Inc. increased its position in shares of Health Catalyst by 78.8% during the second quarter. BlackRock Inc. now owns 4,519,656 shares of the company’s stock worth $250,888,000 after purchasing an additional 1,991,894 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Health Catalyst by 17.8% during the second quarter. Vanguard Group Inc. now owns 3,502,231 shares of the company’s stock worth $194,409,000 after purchasing an additional 530,293 shares in the last quarter. Bank of Montreal Can increased its position in shares of Health Catalyst by 4,269.7% during the second quarter. Bank of Montreal Can now owns 286,874 shares of the company’s stock worth $16,358,000 after purchasing an additional 280,309 shares in the last quarter. Perceptive Advisors LLC increased its position in shares of Health Catalyst by 83.3% during the first quarter. Perceptive Advisors LLC now owns 506,084 shares of the company’s stock worth $23,670,000 after purchasing an additional 230,000 shares in the last quarter. Finally, Point72 Asset Management L.P. acquired a new position in shares of Health Catalyst during the second quarter worth $10,890,000.

Health Catalyst Company Profile

Health Catalyst, Inc engages in the provision of data and analytics technology and services to healthcare organizations. It operates through the Technology, and Professional Services segments. The Technology segment includes its data platform, analytics applications, and support services. The Professional Services segment combines analytics, implementation, strategic advisory, outsource, and improvement services to deliver expertise to its customers.

Further Reading: What is a good dividend yield?

Analyst Recommendations for Health Catalyst (NASDAQ:HCAT)

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.